Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SIFSO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
T-D2-1508
|
|||||
| Synonyms |
T-D2 AZ-1508
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
AZ-1508
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Cysteine D2
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation through reduced inter-chain cysteines (Cys 239)
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 6.40 ng/mL | Moderate HER2 expression (HER2 ++) | ||
| Method Description |
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-361 cells | CVCL_0620 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 1000 ng/mL | Low HER2 expression (HER2 +) | ||
| Method Description |
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
|
||||
| In Vitro Model | Invasive breast carcinoma | T-47D cells | CVCL_0553 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 10.00 ug/mL | Moderate HER2 expression (HER2 ++) | ||
| Method Description |
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-361 cells | CVCL_0620 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 10.00 ug/mL | Low HER2 expression (HER2 +) | ||
| Method Description |
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
|
||||
| In Vitro Model | Invasive breast carcinoma | T-47D cells | CVCL_0553 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.